Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.

@article{Feldman2005PhaseIR,
  title={Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.},
  author={Eric J. Feldman and Joseph E Brandwein and Richard C. Stone and Matt E. Kalaycio and Joseph O. Moore and Julie O'Connor and Nancy Wedel and Gail J. Roboz and Carole Miller and Raj Chopra and Joseph C Jurcic and Randy Brown and William Christopher Ehmann and Philip Schulman and Stanley R. Frankel and Daniel J De Angelo and David A. Scheinberg},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2005},
  volume={23 18},
  pages={4110-6}
}
PURPOSE Lintuzumab (HuM195) is an unconjugated humanized murine monoclonal antibody directed against the cell surface myelomonocytic differentiation antigen CD33. In this study, the efficacy of lintuzumab in combination with induction chemotherapy was compared with chemotherapy alone in adults with first relapsed or primary refractory acute myeloid leukemia (AML). PATIENTS AND METHODS Patients with relapsed or primary resistant AML (duration of first response, zero to 12 months) were randomly… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 71 extracted citations

Similar Papers

Loading similar papers…